Telbivudine

• CAT Number: A000826
• CAS Number: 3424-98-4
• Molecular Formula: C10H14N2O5
• Molecular Weight: 242.23
• Purity: ≥95%
• Target: HBV
• Solubility: >11.9mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1
• InChIKey: IQFYYKKMVGJFEH-CSMHCCOUSA-N
• SMILES: CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O

Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance. Telbivudine is a synthetic thymidine nucleoside analogue; it is the L-isomer of thymidine.

Reference

1: Zheng J, Deng M, Qiu X, Chen Z, Li D, Deng X, Deng Q, Yu Z. Rhabdomyolysis,
lactic acidosis, and multiple organ failure during telbivudine treatment for
hepatitis B: a case report and review of the literature. J Med Case Rep. 2017 Nov
27;11(1):331. doi: 10.1186/s13256-017-1498-6. PubMed PMID: 29179767.

2: Chen B, Chen L, Cheng C, Zhong M, Shi X, Zhang J, Wang B. Determination of
Telbivudine in the Plasma of Chronic Hepatitis B Patients in Long-Term Treatment
by High-Performance Liquid Chromatographic-Tandem Mass Spectrometry. Biomed
Chromatogr. 2017 Nov 17. doi: 10.1002/bmc.4140. [Epub ahead of print] PubMed
PMID: 29148589.

3: Shi H, Han Z, Liu J, Xue J, Zhang S, Zhu Z, Xia J, Huang M. Comparing Efficacy
of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating
Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B
Virus (HBV) DNA Levels. Med Sci Monit. 2017 Nov 2;23:5230-5236. PubMed PMID:
29095799; PubMed Central PMCID: PMC5680675.

4: Liu J, Chen T, Zhao Y. Telbivudine therapy for gravidas with chronic hepatitis
B infection and patients at risk of renal impairment. J Viral Hepat. 2017 Nov;24
Suppl 1:6-11. doi: 10.1111/jvh.12787. Review. PubMed PMID: 29082653.

5: Pan HY, Pan HY, Song WY, Zheng W, Tong YX, Yang DH, Dai YN, Chen MJ, Wang MS,
Huang YC, Zhang JJ, Huang HJ. Long-term outcome of telbivudine versus entecavir
in treating higher viral load chronic hepatitis B patients without cirrhosis. J
Viral Hepat. 2017 Nov;24 Suppl 1:29-35. doi: 10.1111/jvh.12794. PubMed PMID:
29082652.

6: Luo XD, Chen XF, Zhou Y, Chen XP. Comparison of 208-week sequential therapy
with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients
with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled,
randomized, controlled, /real-life/ trial. J Viral Hepat. 2017 Nov;24 Suppl
1:36-42. doi: 10.1111/jvh.12790. PubMed PMID: 29082651.

7: Yi W, Li MH, Xie Y, Wu J, Hu YH, Zhang D, Zhang Y, Cao WH. Prospective cohort
study on the efficacy and safety of telbivudine used throughout pregnancy in
blocking mother-to-child transmission of hepatitis B virus. J Viral Hepat. 2017
Nov;24 Suppl 1:49-56. doi: 10.1111/jvh.12788. PubMed PMID: 29082650.

8: Liu J, Yao N, Zhao Y. Improvement of telbivudine on renal function and massive
proteinuria: A case report. J Viral Hepat. 2017 Nov;24 Suppl 1:75-77. doi:
10.1111/jvh.12789. PubMed PMID: 29082647.

9: Shang J, Wen Q, Wang CC, Liu K, Bai L, Tang H. Safety and efficacy of
telbivudine for chronic hepatitis B during the entire pregnancy: Long-term
follow-up. J Viral Hepat. 2017 Nov;24 Suppl 1:43-48. doi: 10.1111/jvh.12785.
PubMed PMID: 29082646.

10: Liu JF, Wang J, Guo DD, Qi CJ, Cao FR, Tian Z, Yao NJ, Wu YC, Yang Y, He YL,
Zhao YR, Chen TY. [Predictive value of single nucleotide polymorphisms of HLA-C
and UBE2L3 in evaluating the effect of telbivudine antiviral therapy during
pregnancy]. Zhonghua Gan Zang Bing Za Zhi. 2017 Aug 20;25(8):601-605. doi:
10.3760/cma.j.issn.1007-3418.2017.08.009. Chinese. PubMed PMID: 29056010.